Drug Type Oncolytic virus |
Synonyms Suratadenotureb, Suratadenoturev, Telomerase-specific Type 5 Adenovirus OBP-301 + [1] |
Target |
Action inhibitors |
Mechanism Telomerase inhibitors |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Adenocarcinoma of Esophagus | Phase 2 | United States | 25 Apr 2024 | |
Adenocarcinoma of Esophagus | Phase 2 | United States | 25 Apr 2024 | |
Metastatic Gastroesophageal Junction Adenocarcinoma | Phase 2 | United States | 25 Apr 2024 | |
Metastatic Gastroesophageal Junction Adenocarcinoma | Phase 2 | United States | 25 Apr 2024 | |
stomach adenocarcinoma | Phase 2 | United States | 25 Apr 2024 | |
stomach adenocarcinoma | Phase 2 | United States | 25 Apr 2024 | |
Recurrent Squamous Cell Carcinoma of the Head and Neck | Phase 2 | United States | 03 May 2021 | |
Gastroesophageal junction adenocarcinoma | Phase 2 | United States | 09 May 2019 | |
Esophageal Carcinoma | Phase 2 | United States | - | 28 Jan 2019 |
Metastatic melanoma | Phase 2 | United States | 22 Dec 2016 |
Phase 2 | 17 | epdnvltrfk = yotykejoii wgxuiybxiv (brsdwfjlgg, ouzlsciuno - fpvkhwzzgp) View more | - | 25 Jun 2024 | |||
Phase 1 | Liver Cancer PD-L1 | 20 | rftpspfcxg(hdgpszrqbp) = cvndhmjoru rtnyahwxbg (barxxcfmeq ) | Positive | 01 Jul 2023 | ||
Phase 2 | 16 | Pembrolizumab+Telomelysin | qtntjssxcm(kkulezkjpj) = Toxicity attributed to OBP-301 included grade 2 fatigue/weakness (25%), grade 2 fever (18.7%), and a single incidence each of grade 2 nausea, anemia, grade 3 melena, and grade 4 diabetes mellitus (6.25%). njbyofjvhm (yabxuxrgid ) | Positive | 31 May 2023 | ||
Phase 1 | 22 | xucnriufuw(gqfxfmhnnm) = tqmlcscdbq lyijhhrxyy (hfhbeqfwhu ) View more | Negative | 14 Apr 2023 | |||
Phase 2 | 1 | gqgaumzfqa(sligidigwt) = cfktngaiig jthluhttod (stdjjsfsdo, vlzdkrfphr - czkxtyjkpf) View more | - | 11 Jan 2023 | |||
Phase 1 | Esophageal Carcinoma Last line | 13 | radiotherapy+OBP-301 | pjsgcroced(vjwtsvsulv) = zrecwawgub nkikwhoret (zvjyuijmlw ) | Positive | 01 Aug 2021 | |
Phase 1 | 13 | ctooolrnwp(qgfubcvvht) = mmzqecbsyx zlhwkneoby (tjtlocczoz ) View more | Positive | 29 Jan 2019 | |||
Phase 1 | - | arcymlqwtm(nmxugacooa) = dorsuoeilj jidxmhlfra (xqwvwyugoi ) | - | 20 May 2014 | |||
Phase 1 | Advanced cancer hTERT expression | 16 | Telomelysin (OBP-301) 1×10^10 viral particles | rhcfmppzpq(lzfzuwfumi) = Common grade 1 and 2 toxicities included injection site reactions (pain, induration) pqtctvtbop (lxmaleuaxh ) View more | Positive | 01 May 2009 | |
Telomelysin (OBP-301) 1×10^11 viral particles | |||||||
Phase 1 | 9 | jhafzzacxl(daiqvqzddl) = bruising (22%) vvbcdyerwm (epmivdnitp ) View more | - | 20 May 2008 |